(Q35068022)

6 August 2017

1 reference

title

The management of alcoholic liver disease (English)

1 reference

6 August 2017

Stephen F Stewart

1

1 reference

6 August 2017

Christopher P Day

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Journal of Hepatology

1 reference

6 August 2017

volume

38 Suppl 1

1 reference

6 August 2017

page(s)

S2-13

1 reference

Changes in levels of alcohol consumption: United States, 1983-1988

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

EFFECTS OF PROLONGED ETHANOL INTAKE: PRODUCTION OF FATTY LIVER DESPITE ADEQUATE DIETS.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Brief interventions for alcohol problems: a meta-analytic review of controlled investigations in treatment-seeking and non-treatment-seeking populations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Benefit-cost analysis of brief physician advice with problem drinkers in primary care settings

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Project MATCH: treatment main effects and matching results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Pharmacological treatment of alcohol dependence: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Disulfiram treatment of alcoholism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Disulfiram treatment of alcoholism. A Veterans Administration cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

The disulfiram and calcium carbimide acetaldehyde-mediated ethanol reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Severity of alcohol dependence in patients with alcoholic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

A randomized trial of prednisolone in patients with severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Alcoholic liver disease: new insights into mechanisms and preventative strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Inactivation of Kupffer cells prevents early alcohol-induced liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Antibiotics prevent liver injury in rats following long-term exposure to ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Current concepts in the pathogenesis of alcoholic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Regulation of inducible gene expression by the transcription factor NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Glucocorticosteroids are not effective in alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Increased tumor necrosis factor production by monocytes in alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Increased plasma tumor necrosis factor in severe alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Aminoacid therapy of alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Effect of parenteral amino acid supplementation in alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Changes in liver nucleotide concentrations in experimental liver injury. 2. Acute ethanol poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Spin trapping of free radical species produced during the microsomal metabolism of ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Oxidative stress-related molecules and liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Monitoring oxidative damage in patients with liver cirrhosis and different daily alcohol intake

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

In situ detection of lipid peroxidation by-products in chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Lipid peroxidation and hepatic antioxidants in alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

S-adenosyl-L-methionine: its effect on aminolevulinate dehydratase and glutathione in acute ethanol intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Low blood selenium levels in alcoholics with and without advanced liver disease. Correlations with clinical and nutritional status.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Hepatic vitamin A depletion in alcoholic liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Influence of Protracted Infusion of Glucose and Insulin on the Composition and Regeneration Activity of Liver after Partial Hepatectomy in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Effect of insulin and glucagon on fulminant murine hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: A multicenter sequential trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Managing severe alcoholic hepatitis complicated by renal failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

A 20-year prospective study of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Long-term treatment of alcoholic liver disease with propylthiouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Effects of antimicrotubular agents on the secretion of collagen. A biochemical and morphological study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Inhibition of Collagen Secretion from Bone and Cultured Fibroblasts by Microtubular Disruptive Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Colchicine in the treatment of cirrhosis of the liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Lack of effect of colchicine in alcoholic cirrhosis: final results of a double blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Antioxidant activity of silybin in vivo during long-term iron overload in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Alcoholic liver disease: new insights in pathogenesis lead to new treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Liver transplantation for alcoholic liver disease in the United States: 1988 to 1995

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Transplantation for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Prognosis and life expectancy in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Alcohol use following liver transplantation for alcoholic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Alcohol use after liver transplantation in alcoholics: a clinical cohort follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Orthotopic liver transplantation for alcoholic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Liver transplantation for alcoholic liver disease: evaluation of a selection protocol.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Histological features after liver transplantation in alcoholic cirrhotics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Assessing priorities for allocation of donor liver grafts: survey of public and clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Is liver transplantation an appropriate treatment for acute alcoholic hepatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Survival and quality of life after liver transplantation for acute alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900427-0

7 January 2021

10.1016/S0168-8278(02)00427-0

Identifiers

DOI

1 reference

6 August 2017

1 reference